IRONDisc Medicine, Inc.
Pharmaceutical Preparations
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$236M
- 82% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$39M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Operating income | −$31M | −$47M | −$91M | −$130M | −$236M | 82% |
| Net income | −$36M | −$47M | −$76M | −$109M | −$212M | 94% |
| Operating cash flow | −$28M | −$42M | −$73M | −$94M | −$180M | 92% |
| Capex | $68K | $151K | $89K | $505K | $933K | 85% |
| Stock-based comp | $507K | $2M | $6M | $17M | $34M | 104% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $5M · 13
- Net
- −$5M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $10M | $13M | 258 | 120 |
| FY2024 | $9M | $9M | 206 | 91 |
| FY2023 | $909K | $5M | 188 | 92 |
| FY2022 | $2M | $1M | 65 | 88 |